RT Journal Article
SR Electronic
T1 Profiling Genome-Wide DNA Methylation Patterns in Human Aortic and Mitral Valves
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.10.20190546
DO 10.1101/2020.09.10.20190546
A1 Sarah Halawa
A1 Najma Latif
A1 Yuan-Tsan Tseng
A1 Ayman M. Ibrahim
A1 Adrian H. Chester
A1 Ahmed Moustafa
A1 Yasmine Aguib
A1 Magdi Yacoub
YR 2020
UL http://medrxiv.org/content/early/2020/09/11/2020.09.10.20190546.abstract
AB Cardiac valves exhibit highly complex structures and specialized functions that include dynamic interactions between cells, extracellular matrix (ECM) and their hemodynamic environment. Valvular gene expression is tightly regulated by a variety of mechanisms including epigenetic factors such as histone modifications, RNA-based mechanisms and DNA methylation. To date, methylation fingerprints of non-diseased human aortic and mitral valves have not been studied. In this work we analyzed the differential methylation profiles of 12 non-diseased aortic and mitral valve tissue samples (in matched pairs). Analysis of methylation data (reduced representation bisulfite sequencing (RRBS)) of 1601 promoters genome-wide revealed 584 differentially methylated (DM) promoters, of which 13 were reported in endothelial mesenchymal trans-differentiation (EMT), 37 in aortic and mitral valve disease and 7 in ECM remodeling. Both functional classification as well as network analysis showed that the genes associated with the DM promoters were enriched for WNT-, Cadherin-, Endothelin-, PDGF- and VEGF-signaling implicated in valvular physiology and pathophysiology. Additional enrichment was detected for TGFB-, NOTCH- and Integrin-signaling involved in EMT as well as ECM remodeling. This data provides the first insight into differential regulation of human aortic and mitral valve tissue and identifies candidate genes linked to DM promoters. Our work will improve the understanding of valve biology, valve tissue engineering approaches and contributes to the identification of relevant drug targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Magdi Yacoub Institute (MYI) and Magdi Yacoub Foundation (MYF). Sarah Halawa was partially supported by Al Alfi Foundation (Al Alfi PhD Fellowship in Applied Sciences and Engineering).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Royal Brompton hospital ethics review board / Brompton and Harefield trust ethics committee (REC approval 10/H0724/18) and is abiding by all the standards of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data was deposited in the European Genome-phenome Archive (EGA) and is accessible through the accession number EGAD00001006303. https://www.ebi.ac.uk/ega/studies/EGAS00001004559